How Health Savings Accounts Are Powering the Rise of Direct Pay in Medicine
The American healthcare system is quietly undergoing a financial transformation. As insurance premiums rise and administrative complexity deepens, more patients—and ...
The Hidden Link: How Atrial Fibrillation May Accelerate Dementia Risk
Cardiologists and neurologists have long viewed atrial fibrillation (AFib) and dementia as two distinct clinical challenges. But a growing body ...
The Data Dilemma: What 23andMe’s Bankruptcy Means for the Future of Medical Data Ownership
The news of 23andMe’s financial instability and potential bankruptcy isn’t just another tech-company flameout. It’s a watershed moment for the ...
Tariffs, Trade Wars, and Healthcare: The Hidden Costs of Economic Policy
As the U.S. retools its trade policies in an increasingly fractured global economy, tariffs—once seen as abstract economic levers—are becoming ...
Leadership Shakeups at DHHS, CDC, and FDA Threaten Long-Term Healthcare Policy Stability
Recent months have seen a steady exodus of senior leadership across the Department of Health and Human Services (DHHS), the ...
From Academia to Algorithms: Vinay Prasad and the Rise of Populist Medicine Online
Healthcare has always existed at the intersection of science, politics, and public trust. But in today’s digital era, the loudest ...
Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get
Retatrutide isn’t FDA-approved. It’s still in clinical trials. But that hasn’t stopped people from trying to get their hands on ...
Telehealth in Turmoil: Can America Preserve Its Pandemic-Driven Progress?
The COVID-19 pandemic served as a catalyst for the rapid adoption of telehealth services across the United States. As in-person ...
Physicians in the Courtroom: Mastering Pro Se Legal Representation
Physicians are no strangers to complexity. Navigating a medical diagnosis or interpreting clinical trial data can be as demanding as ...
How Social Security Disruptions Impact Out-of-Pocket Healthcare Costs
Delays in Social Security payments can leave seniors and disabled individuals struggling to afford out-of-pocket healthcare costs. Learn how disruptions ...
How Dr. Oz Could Use the Affordable Care Act to Dismantle Medicare and Push Privatization
Dr. Mehmet Oz, a prominent figure in conservative health policy, could leverage the Affordable Care Act (ACA) to weaken traditional ...
FDA’s Identity Crisis: Marty Makary, Mass Layoffs, and the Trump-Era Push for Speed Over Safety
The FDA’s Identity Crisis: Marty Makary, Mass Layoffs,and the Trump-Era Push for Speed Over Safety The U.S. Food and Drug ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
The IRA’s Drug Negotiation Mechanism Meets the Rebate Industrial Complex
-
Retatrutide: The Weight Loss Drug Everyone Wants—But Can’t Officially Get
-
Growth Hormone Secretagogues and the Longevity Trade-Off
-
GLP-1 Agonists Beyond Obesity: The Expanding Therapeutic and Optimization Frontier
-
The Second Reader That Never Sleeps: Large Language Models and Clinical Decision-Making
